Silybin is also an inhibitor of expression of the programmed death-ligand 1 (PD-L1) checkpoint immune regulator as well as epithelial-mesenchymal transition (EMT) regulators, and it can be a promising adjuvant in non-small-cell lung carcinoma (NSCLC) [277]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.